JP2020510091A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510091A5
JP2020510091A5 JP2019571788A JP2019571788A JP2020510091A5 JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5 JP 2019571788 A JP2019571788 A JP 2019571788A JP 2019571788 A JP2019571788 A JP 2019571788A JP 2020510091 A5 JP2020510091 A5 JP 2020510091A5
Authority
JP
Japan
Prior art keywords
alkyl
solvate
hydrate
aryl
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019571788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510091A (ja
JP7211982B2 (ja
Filing date
Publication date
Priority claimed from GBGB1704327.4A external-priority patent/GB201704327D0/en
Application filed filed Critical
Publication of JP2020510091A publication Critical patent/JP2020510091A/ja
Publication of JP2020510091A5 publication Critical patent/JP2020510091A5/ja
Application granted granted Critical
Publication of JP7211982B2 publication Critical patent/JP7211982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019571788A 2017-03-17 2018-03-16 Prmt5媒介性障害の治療又は予防に有用な化合物 Active JP7211982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704327.4 2017-03-17
GBGB1704327.4A GB201704327D0 (en) 2017-03-17 2017-03-17 Compounds
PCT/EP2018/056663 WO2018167269A1 (en) 2017-03-17 2018-03-16 Compounds useful in the treatment or prevention of a prmt5-mediated disorder

Publications (3)

Publication Number Publication Date
JP2020510091A JP2020510091A (ja) 2020-04-02
JP2020510091A5 true JP2020510091A5 (enExample) 2021-04-30
JP7211982B2 JP7211982B2 (ja) 2023-01-24

Family

ID=58688233

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571788A Active JP7211982B2 (ja) 2017-03-17 2018-03-16 Prmt5媒介性障害の治療又は予防に有用な化合物

Country Status (13)

Country Link
US (1) US11485731B2 (enExample)
EP (1) EP3596061B1 (enExample)
JP (1) JP7211982B2 (enExample)
KR (1) KR102616970B1 (enExample)
CN (1) CN110650950B (enExample)
AU (2) AU2018235139A1 (enExample)
CA (1) CA3056724A1 (enExample)
GB (1) GB201704327D0 (enExample)
IL (1) IL269354B2 (enExample)
MX (1) MX2019011061A (enExample)
SG (1) SG11201908598PA (enExample)
WO (1) WO2018167269A1 (enExample)
ZA (1) ZA201906269B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
EP3980406A4 (en) * 2019-06-06 2023-06-28 Aligos Therapeutics, Inc. Heterocyclic compounds
CN110950841A (zh) * 2019-11-22 2020-04-03 济南大学 一类新型三唑类化合物的合成及应用
EP4076459A4 (en) * 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
KR20230012041A (ko) * 2020-06-02 2023-01-25 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 3,4-디하이드로이소퀴놀린계 화합물 및 그 사용
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
AU2021300483A1 (en) * 2020-06-30 2023-02-09 Nanjing Zaiming Pharmaceutical Co., Ltd. Tetrahydroisoquinoline compounds and use thereof
EP4209485A4 (en) 2020-09-04 2025-02-19 Innovstone Therapeutics Limited ASSOCIATES WITH ANTI-TUMOOR ACTIVITY AND USE THEREOF
MX2023009682A (es) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Inhibidores de tyk2 y sus usos.
KR20230159421A (ko) 2021-02-19 2023-11-21 수도 바이오사이언시즈 리미티드 Tyk2 억제제 및 이의 용도
WO2022237858A1 (zh) 2021-05-13 2022-11-17 上海翊石医药科技有限公司 一种具有抗肿瘤活性的化合物及其用途
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
GB202117230D0 (en) 2021-11-29 2022-01-12 Argonaut Therapeutics Ltd Peptide vaccine
CA3240466A1 (en) * 2021-12-08 2023-06-15 Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. Salt of 3,4-dihydroisoquinoline compound and use thereof
WO2023125947A1 (zh) * 2021-12-30 2023-07-06 江苏先声药业有限公司 四氢异喹啉类化合物的可药用盐、晶型及其用途
WO2023131305A1 (zh) * 2022-01-06 2023-07-13 江苏先声药业有限公司 Prmt5抑制剂和抗癌治疗剂的组合
GB202203588D0 (en) 2022-03-15 2022-04-27 Argonaut Therapeutics Ltd Cancer diagnostic

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016511744A (ja) 2012-12-21 2016-04-21 エピザイム,インコーポレイティド Prmt5を阻害する方法
EP3406607A1 (en) 2012-12-21 2018-11-28 Epizyme, Inc. Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
EP3498701B1 (en) 2012-12-21 2023-02-22 Epizyme Inc Prmt5 inhibitors and uses thereof
US8906900B2 (en) * 2012-12-21 2014-12-09 Epizyme, Inc. PRMT5 inhibitors and uses thereof
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2015200677A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10494376B2 (en) * 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors

Similar Documents

Publication Publication Date Title
JP2020510091A5 (enExample)
JP2019529490A5 (enExample)
JP2019527203A5 (enExample)
JP2018522879A5 (enExample)
JP2018536634A5 (enExample)
JP2017523169A5 (enExample)
JP2016505637A5 (enExample)
JP2016518437A5 (enExample)
JP2016518328A5 (enExample)
JP2019524883A5 (enExample)
JP2012522847A5 (enExample)
JP2019510810A5 (enExample)
JP2019518766A5 (enExample)
JP2020527173A5 (enExample)
JP2016121196A5 (enExample)
RU2012109554A (ru) Лиганды сигма-рецепторов для предупреждения или лечения боли, вызванной химиотерапией
JP2016537382A5 (enExample)
JP2016506958A5 (enExample)
JP2012524056A5 (enExample)
JP2019530699A5 (enExample)
JP2014521688A5 (enExample)
JP2017508782A5 (enExample)
RU2016134751A (ru) Соединения
JP2018531218A5 (enExample)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤